Trials / Completed
CompletedNCT00499993
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
Phase III, Multicentre, Open Clinical Study on the Efficacy and Tolerability of a New Slow-release Formulation of Lanreotide (Autogel 120 mg) in Patients With Active Acromegaly
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the protocol, is to evaluate if lanreotide Autogel 120 mg is effective in the control of Growth Hormone (GH) secretion in patients with active acromegaly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lanreotide (Autogel formulation), duration of treatment 46-48 weeks |
Timeline
- Start date
- 2001-01-01
- Completion
- 2003-05-01
- First posted
- 2007-07-12
- Last updated
- 2019-01-15
Locations
24 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00499993. Inclusion in this directory is not an endorsement.